Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Yoon Jin ChaHye Ryun KimHyo Sup ShimPublished in: Journal of translational medicine (2016)
Among ALK fusion variants, v1 is the most common subtype. It showed superior progression-free survival on pemetrexed than did non-EML4 variants. No survival difference was demonstrated between variants treated with crizotinib or ceritinib.